13F filer · CIK 1839948
TCG Crossover Management, LLC
PALO ALTO, CA · filing since Q4 2021 · last filing Aug 14, 2026
Reported value
$4.2B
+$665.1M vs prior
Positions
54
New / sold out
12 / 7
Added / reduced
2 / 9
Turnover
12.4%
buys $475.1M · sells $492.4M
Top-10 weight
57.4%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | ZAI LAB LTD-ADR | +6,137,627 | – | +$116.6M |
| New | AURA BIOSCIENCES INC | +9,533,333 | – | +$67.7M |
| New | FIRST TRACKS BIOTHERAPEUTICS | +2,895,304 | – | +$58.3M |
| Added | AVALO THERAPEUTICS INC | +2,278,737 | +308.6% | +$42.1M |
| New | EDITAS MEDICINE INC | +11,111,111 | – | +$36.0M |
| New | PHARVARIS BV | +1,008,229 | – | +$34.9M |
| New | INFLARX N V | +14,500,000 | – | +$32.5M |
| New | ALTIMMUNE INC | +10,000,000 | – | +$30.4M |
| New | AKTIS ONCOLOGY INC | +696,560 | – | +$22.5M |
| New | FORTE BIOSCIENCES INC | +920,000 | – | +$19.6M |
4 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | CENTESSA PHARMACEUTICALS PLC | -4,286,480 | -100.0% | $-170.3M |
| Reduced | ABIVAX SA AMERICAN DEPOSITARY SHARES | -473,251 | -7.3% | $-63.1M |
| Reduced | TANGO THERAPEUTICS INC | -1,449,870 | -13.8% | $-45.3M |
| Reduced | REVOLUTION MEDICINES INC | -235,574 | -40.9% | $-44.1M |
| Reduced | BIOHAVEN LTD | -2,851,365 | -61.6% | $-42.4M |
| Sold out | FULCRUM THERAPEUTICS INC | -5,250,000 | -100.0% | $-40.3M |
| Reduced | ALX ONCOLOGY HOLDINGS INC | -7,356,362 | -56.5% | $-15.2M |
| Sold out | LIQUIDIA TECHNOLOGIES INC | -403,048 | -100.0% | $-15.2M |
| Reduced | ARVINAS HOLDING CO LLC | -1,680,363 | -70.4% | $-14.0M |
| Reduced | LB PHARMACEUTICALS INC | -392,179 | -21.3% | $-12.7M |
6 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | ABIVAX SA AMERICAN DEPOSITARY SHARESCOMM | 6,007,834 | $800.6M | 19.24% |
| 2 | TANGO THERAPEUTICS INCCOMM | 9,081,201 | $283.9M | 6.82% |
| 3 | CG ONCOLOGY INCCOMM | 3,670,206 | $260.8M | 6.27% |
| 4 | COGENT BIOSCIENCES INCCOMM | 4,854,436 | $187.9M | 4.52% |
| 5 | IMMUNOVANT INCCOMM | 4,457,988 | $171.8M | 4.13% |
| 6 | SPYRE THERAPEUTICS INCCOMM | 1,900,582 | $168.7M | 4.06% |
| 7 | DIANTHUS THERAPEUTICS INCCOMM | 1,676,624 | $163.4M | 3.93% |
| 8 | MIRUM PHARMACEUTICALS INCCOMM | 1,062,049 | $124.3M | 2.99% |
| 9 | ZAI LAB LTD-ADRADRS | 6,137,627 | $116.6M | 2.80% |
| 10 | AMYLYX PHARMACEUTICALS INCCOMM | 6,243,812 | $112.1M | 2.70% |
44 more rows. Subscribe for $29/month to see every row, download the data and use the API.